Head-to-head · free
uniQure vs Revolution Medicines, Inc.
QURE vs RVMD — return on capital, cash generation, margins and balance sheet side by side.
QURE
3 / 4
measures where QURE leads
RVMD
1 / 4
measures where RVMD leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | QURE · FY2025 | RVMD · FY2025 |
|---|---|---|
| Revenue | — | $0 |
| Net income | (199.0M) | (1.1B) |
| Revenue growth (yearly, multi-year) | -47.8% | -37.2% |
| Free cash flow | (178.4M) | (913.7M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | — | -58.1% |
| Gross margin | 89.5% | — |
| Operating margin | -1166.8% | — |
| Net debt / EBITDA | 0.18x | 0.33x |
Figures are as reported by each company; latest fiscal year shown.
Where uniQure's cash went (FY2025)
- Capital spending
- $439000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Revolution Medicines, Inc.'s cash went (FY2025)
- Capital spending
- $16.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free